Stock P09 PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Pacific Biosciences of California, Inc. Deutsche Boerse AG

Equities

P09

US69404D1081

Market Closed - Deutsche Boerse AG
Other stock markets
 11:16:35 2024-04-29 am EDT 		5-day change 1st Jan Change
1.551 EUR +15.51% Intraday chart for Pacific Biosciences of California, Inc. +9.06% -82.49%
Apr. 22 JPMorgan Downgrades Pacific Biosciences of California to Neutral From Overweight MT
Apr. 18 Scotiabank Adjusts Pacific Biosciences of California's Price Target to $8 From $15, Maintains Sector Outperform Rating MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
JPMorgan Downgrades Pacific Biosciences of California to Neutral From Overweight
MT
Scotiabank Adjusts Pacific Biosciences of California's Price Target to $8 From $15, Maintains Sector Outperform Rating
MT
Goldman Sachs Downgrades Pacific Biosciences of California to Neutral From Buy, Adjusts Price Target to $2.50 From $7
MT
TD Cowen Adjusts Price Target on Pacific Biosciences of California to $2.50 From $12, Maintains Buy Rating
MT
Sector Update: Health Care Stocks Higher Late Afternoon
MT
Sector Update: Health Care
MT
Pacific Biosciences of California Q1 Revenue Expected to Be Flat Year Over Year; Guidance Lowered; Shares Sink
MT
PacBio Announces Preliminary First Quarter 2024 Revenue and Updates 2024 Revenue Guidance
PR
Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2024
CI
Goldman Sachs Cuts Price Target on Pacific Biosciences of California to $7 From $9, Maintains Buy Rating
MT
Estonia National Biobank Selects PacBio to Sequence 10,000 Whole Genomes
PR
Estonia National Biobank Selects PacBio to Sequence 10,000 Whole Genomes
CI
PacBio Grants Equity Incentive Award to New Employee
PR
Transcript : Pacific Biosciences of California, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 10:15 AM
PacBio Announces PureTarget™ Repeat Expansion Panel, Expanding its Portfolio of End-to-End Clinical Research Solutions
PR
PacBio Announces PureTarget Repeat Expansion Panel, Expanding Its Portfolio of End-To-End Clinical Research Solutions
CI
PacBio to Present at Upcoming Investor Conferences
PR
Federal Circuit Affirms Claim Construction And How It Applies
AQ
UBS Trims Pacific Biosciences of California Price Target to $12 From $12.50, Maintains Buy Rating
MT
Pacific Biosciences of California Q4 Non-GAAP Loss Narrows, Revenue Rises; Shares Drop After Hours
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PACB Stock
  4. P09 Stock
  5. News Pacific Biosciences of California, Inc.